NCT05991895 Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
| NCT ID | NCT05991895 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jinming Yu |
| Condition | Non-small Cell Lung Cancer (NSCLC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2023-07-24 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2023-07-24 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a national multicenter real-world investigation aimed at evaluating the real-world effectiveness and safety of Iruplinalkib in the treatment of ALK-positive NSCLC in China. The study aims to enroll ALK-positive NSCLC patients who have undergone treatment with Iruplinalkib prior to enrollment. Demographic information, medical history, Iruplinalkib-containing treatment regimens, clinical outcomes, adverse events, and related data will be collected for all enrolled patients. As this study is a real-world investigation, treatment procedures, visit schedules, and examinations will be based on the routine clinical practice of physicians. The primary sources of data for this study will mainly consist of patients' routine medical records or healthcare documentation.
Eligibility Criteria
Inclusion Criteria: * Patients willingly contribute their clinical data for this study * Patients with ALK-positive non-small cell lung cancer * Age ≥ 18 years * Patients who have undergone treatment with Iruplinalkib. Exclusion Criteria: * Known pregnant or lactating females * Patients with interstitial lung diseases, drug-related pneumonitis, or radiation pneumonitis require ongoing medical intervention.
Contact & Investigator
JinMing Yu, PhD
PRINCIPAL INVESTIGATOR
Shandong Cancer Hospital and Institute
Frequently Asked Questions
Who can join the NCT05991895 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-small Cell Lung Cancer (NSCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05991895 currently recruiting?
Yes, NCT05991895 is actively recruiting participants. Contact the research team at jn7984729@public.jn.sd.cn for enrollment information.
Where is the NCT05991895 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT05991895 clinical trial?
NCT05991895 is sponsored by Jinming Yu. The principal investigator is JinMing Yu, PhD at Shandong Cancer Hospital and Institute. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.